Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — The U.K.-based drugmaker GSK said early Wednesday that it planned to invest $30 billion in the U.S. over five years, an announcement timed to this week’s state visit here by President Trump. The company,…
Health Tech Correspondent Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech…
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. STAT’s (newly-certified!) fitness instructor Chelsea Cirruzzo took a look at the MAHA Moms strength challenge, and pronounced it a “pretty solid” no-equipment workout, thanks…
Top of the morning to you, and a fine one it is. Despite gray skies hovering over the Pharmalot campus, the air is cool and the surrounding environs are surprisingly quiet, except for the official mascots who are chasing their breakfast. The Pharmalot grounds are filled with tasty treats. As for us, we are engaged…
The summer has been filled with debates about the safety of Elevidys, Sarepta’s gene therapy for Duchenne muscular dystrophy. Four prominent researchers are now raising a fundamental question about its efficacy: How much gene does the gene therapy actually deliver? In principle, the question should be settled. Since its first trial in 2017, Sarepta has…
WASHINGTON — Congress is again discussing the Trump administration’s plan to force drug companies to lower their U.S. prices, at least behind the scenes. Congressional staffers and health policy experts from major think tanks held a closed-door meeting to discuss policy options that would peg U.S. prices for drugs to what other countries pay, called…
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which…
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to shop for a new tool to help us manicure the Pharmalot grounds, catch up on…
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have clear skies and delicious, cool breezes. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for another cup of…